喘可治治疗慢性阻塞性肺疾病缓解期的临床疗效及对炎性因子水平的影响
|
摘要
目的分析喘可治治疗慢性阻塞性肺疾病(COPD)缓解期的临床疗效及炎性因子水平的影响。方法选取我院2015年12月至2017年10月收治的80例COPD患者,随机分为对照组和观察组各40例。对照组用氨溴索缓释胶囊、茶碱缓释片、布地奈德福莫特罗粉吸入剂治疗,观察组在此基础上采用喘可治注射液雾化治疗,两组患者治疗7 d为1个疗程,共治疗12个疗程。对比两组患者治疗前后的FEV_1、 FEV_1/FVC、 TNF-α、 IL-6、 IL-8水平。结果治疗前,两组患者的FEV_1、 FEV_1/FVC水平比较差异无统计学意义(P>0.05);治疗后,两组的FEV1、 FEV_1/FVC水平提高(P <0.05),且观察组的FEV_1、 FEV_1/FVC水平明显高于对照组(P <0.05)。治疗前,两组患者的TNF-α、 IL-6、 IL-8水平比较差异无统计学意义(P>0.05);治疗后,两组的TNF-α、 IL-6、 IL-8水平下降(P <0.05),且观察组的TNF-α、 IL-6、 IL-8水平明显低于对照组(P <0.05)。结论常规治疗联合喘可治治疗COPD缓解期患者可有效改善患者的肺功能,抑制气道炎性因子的表达,减轻气道慢性炎症。
Objective To analyze the clinical efficacy of Chuankezhi in the treatment of chronic obstructive pulmonary disease(COPD) during remission and the influence on inflammatory factor levels. Methods 80 cases of COPD patients admitted to our hospital from December 2015 to October 2017 were selected and randomly divided into control group and observation group, with 40 cases in each group.The control group was treated with ambroxol sustained-release capsules, theophylline sustained-release tablets and budesonide formoterol powder inhalation, while the observation group was treated with aerosol inhalation of Chuankezhi injection on this basis. Both groups were treated for 12 courses(7 days as a course). The FEV1, FEV1/FVC, TNF-α, IL-6 and IL-8 levels before and after treatment were compared between the two groups. Results Before treatment, no statistical difference was found in the FEV1 and FEV1/FVC levels between the two groups(P >0.05). After treatment, the FEV1 and FEV1/FVC levels of the two groups increased(P <0.05), and the FEV1 and FEV1/FVC levels of the observation group were significantly higher than those of the control group(P <0.05). Before treatment, no statistical difference was found in the TNF-α, IL-6 and IL-8 levels between the two groups(P >0.05). After treatment, the TNF-α, IL-6 and IL-8 levels of the two groups decreased(P <0.05), and the TNF-α, IL-6 and IL-8 levels of the observation group were significantly lower than those of the control group(P <0.05). Conclusions Routine treatment combined with Chuankezhi in patients with COPD during remission can effectively improve the lung function, inhibit the expression of airway inflammatory factors, and reduce airway chronic inflammation.
Objective To analyze the clinical efficacy of Chuankezhi in the treatment of chronic obstructive pulmonary disease(COPD) during remission and the influence on inflammatory factor levels. Methods 80 cases of COPD patients admitted to our hospital from December 2015 to October 2017 were selected and randomly divided into control group and observation group, with 40 cases in each group.The control group was treated with ambroxol sustained-release capsules, theophylline sustained-release tablets and budesonide formoterol powder inhalation, while the observation group was treated with aerosol inhalation of Chuankezhi injection on this basis. Both groups were treated for 12 courses(7 days as a course). The FEV1, FEV1/FVC, TNF-α, IL-6 and IL-8 levels before and after treatment were compared between the two groups. Results Before treatment, no statistical difference was found in the FEV1 and FEV1/FVC levels between the two groups(P >0.05). After treatment, the FEV1 and FEV1/FVC levels of the two groups increased(P <0.05), and the FEV1 and FEV1/FVC levels of the observation group were significantly higher than those of the control group(P <0.05). Before treatment, no statistical difference was found in the TNF-α, IL-6 and IL-8 levels between the two groups(P >0.05). After treatment, the TNF-α, IL-6 and IL-8 levels of the two groups decreased(P <0.05), and the TNF-α, IL-6 and IL-8 levels of the observation group were significantly lower than those of the control group(P <0.05). Conclusions Routine treatment combined with Chuankezhi in patients with COPD during remission can effectively improve the lung function, inhibit the expression of airway inflammatory factors, and reduce airway chronic inflammation.
引文
[1] Vorster MJ, Koegelenberg CF. Lung volume reduction in chronic obstructive pulmonary disease[J]. S Afr Med J, 2015, 105(9):791.
[2] Vestbo J, Hurd SS, AgustíAG, et al. Global strategy for the diagnosis,management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary[J]. Am J Respir Crit Care Med, 2013,187(4):347-365.
[3] Henderson J, Harrison C, Miller G. Management of COPD in general practice[J]. Aust Fam Physician, 2012, 41(11):841.
[4]中华医学会呼吸病学分会慢性阻塞性肺疾病组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志, 2007,30(1):8-17.
[5]杨平,张艳玲,彭敏.培土生金针刺法对COPD缓解期患者生活质量的影响[J].辽宁中医药大学学报, 2009, 11(3):149-150.
[6]钱海云.喘可治治疗反复呼吸道感染的疗效观察[J].吉林医学,2011, 32(28):5891-5892.
[2] Vestbo J, Hurd SS, AgustíAG, et al. Global strategy for the diagnosis,management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary[J]. Am J Respir Crit Care Med, 2013,187(4):347-365.
[3] Henderson J, Harrison C, Miller G. Management of COPD in general practice[J]. Aust Fam Physician, 2012, 41(11):841.
[4]中华医学会呼吸病学分会慢性阻塞性肺疾病组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志, 2007,30(1):8-17.
[5]杨平,张艳玲,彭敏.培土生金针刺法对COPD缓解期患者生活质量的影响[J].辽宁中医药大学学报, 2009, 11(3):149-150.
[6]钱海云.喘可治治疗反复呼吸道感染的疗效观察[J].吉林医学,2011, 32(28):5891-5892.